Active ingredientOzanimodCat. No. P-O083-001CAS 1306760-87-1Family · Pharmaceutical analytical standards
Ozanimod
A sphingosine-1-phosphate receptor modulator that stops lymphocytes from reaching the brain: approved in the United States in 2020 for relapsing forms of multiple sclerosis, and later also for ulcerative colitis. This family brings together the active ingredient, metabolites, labelled standards and other impurities.
Did you know?It was born in a research institute: Hugh Rosen and Edward Roberts invented it at Scripps Research, in California, building on studies published between 2002 and 2008.
Go to the active ingredient →Active ingredientOzanimodCat. No. P-O083-001CAS 1306760-87-1
Active ingredientOzanimod hydrochlorideCat. No. P-O083-002CAS 1618636-37-5
MetaboliteOzanimod Metabolite 1Cat. No. P-O083-003CAS 2251699-84-8
MetaboliteOzanimod Metabolite of CC1084037Cat. No. P-O083-004CAS 1201447-05-3
Isotopically labelledOzanimod-d6Cat. No. P-O083-005
Impurity(R)-Ozanimod HydrochlorideCat. No. P-O083-006CAS 1306760-85-9
Impurity3-Cyano-4-isopropoxybenzoic acidCat. No. P-O083-007CAS 258273-31-3
ImpurityOzanimod Impurity 1Cat. No. P-O083-008CAS 1306760-73-5
ImpurityOzanimod Impurity 2Cat. No. P-O083-009CAS 2990018-57-8No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.